Cancelled by the investigator Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)

Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030478

Enrollment

Unknown

Registered

2020-03-03

Start date

2020-02-26

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment p

Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatm

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease; 2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung; 3) Inpatients aged 18 to 75 years male or female; 4) Volunteer to receive treatment under their own scheme and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease; 2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; 3) Those who are allergic to the research drug and its main ingredients; 4) pregnant or lactating women; 5) Those who have difficulty taking medicine orally.

Design outcomes

Primary

Measure	Time frame
lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;	—

Secondary

Measure	Time frame
Comparison of TCM symptom score (degree of fever, cough, sputum, chest tightness, shortness of breath, anorexia, abdominal distension, the tongue proper and the tongue coating, pulse condition);comparison of changes in SpO2, oxygen saturation, lymphocyte count;Clinical recovery time: the body temperature returned to normal and lasting for more than 3 days, the respiratory symptoms improved significantly, and the test result was negative for two consecutive times (ended at the time of the first negative result);Comparison of conversion rates of severe (severe or critical) subjects in each group;Comparison of changes in inflammation indicators (white blood cell count, C-reactive protein, ESR, procalcitonin) before and after treatment;	—

Measure

Time frame

Comparison of TCM symptom score (degree of fever, cough, sputum, chest tightness, shortness of breath, anorexia, abdominal distension, the tongue proper and the tongue coating, pulse condition);comparison of changes in SpO2, oxygen saturation, lymphocyte count;Clinical recovery time: the body temperature returned to normal and lasting for more than 3 days, the respiratory symptoms improved significantly, and the test result was negative for two consecutive times (ended at the time of the first negative result);Comparison of conversion rates of severe (severe or critical) subjects in each group;Comparison of changes in inflammation indicators (white blood cell count, C-reactive protein, ESR, procalcitonin) before and after treatment;

—

Countries

China

Contacts

Public ContactHaibin Ni

Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine

nhb_2002@126.com+86 15312019183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026